INTRODUCTION
Developing B cells generate a vast repertoire of antibody specificities through somatic recombination of distinct variable (V), diversity (D) (heavy chain only), and joining (J) genes to form the variable domain exons of immunoglobulins (IG) 1 . Unlike heavy chain complementarity determining regions (HCDR) 1 and 2, which are entirely encoded by the IGHV gene, HCDR3 is created de novo by the VDJ recombination process 1 . The skewing of diversity to the HCDR3 implies that HCDR3
sequences are the principal determinants of specificity, at least in the primary repertoire [2] [3] . However, HCDR3 diversity is not enough to realize the full potential of antibody diversity 4 . Furthermore, unconventional antigens, such as B cell superantigens, may be recognized not via the CDRs but rather via the framework regions (FRs) 5 .
Somatic hypermutation (SHM) of IG variable genes forms a second round of diversification after somatic recombination which increases antibody diversity 6 . SHM has long been thought to occur mainly in the germinal centers (GCs) after antigen stimulation and in a manner dependent on T cell help 7 . Recent reports, however, suggest that SHM can be T cell independent and may also occur outside classical GCs [8] [9] [10] [11] [12] [13] .
In recent years, the mutational status of IGHV genes has been established as one of the most important molecular genetic markers in defining prognostic subgroups of chronic lymphocytic leukemia (CLL). CLL patients who carry IGHV genes with ≥ 98% identity to the closest germline gene ("unmutated") follow a more aggressive clinical course and have strikingly shorter survival than patients carrying IGHV genes with <98% identity to germline ("mutated") [14] [15] . The 98% cut-off was chosen as a short cut to exclude potential polymorphic variants [16] [17] [18] [19] and has been used by the vast majority of studies to make the clinically relevant distinction between "mutated" and "unmutated" cases. Initially it was assumed that CLL cells expressing unmutated IGHV genes derived from naïve B cells. Nevertheless, it was subsequently demonstrated that all CLL cells, irrespective of IGHV gene mutation status, have a surface phenotype typical of antigen-experienced B cells and show gene expression profiles similar to memory B cells 14, [20] [21] [22] [23] .
The CLL IG repertoire is characterized by over-representation of selected IGHV genes, in particular IGHV1-69, IGHV4-34, IGHV3-7 and IGHV3-21, although their relative frequencies vary between cohorts 14, [24] [25] [26] [27] . SHM does not appear to occur uniformly among IGHV genes: for example, the IGHV1-69 gene is consistently
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Recently, multiple CLL subsets with distinctive IG heavy and light chain gene rearrangements were characterized and found to have remarkably stereotyped HCDR3 sequences within their B cell receptors (BCRs) [27] [28] [29] [30] [31] [32] [33] [34] . The expression of stereotyped BCRs was reported as significantly more frequent among CLL patients with unmutated vs. mutated IGHV genes 32, 34 . CLL cases expressing stereotyped
BCRs may also share unique molecular and clinical features, suggesting that a particular antigen-binding site can make a difference in terms of clinical presentation and possibly prognosis 30, 34 . For instance, the IGHV3-21/IGLV3-21 subset should be regarded as unfavorable whatever the degree of mutation 35 , whereas the IGHV4-34/IGKV2-30 subset seems to be associated with an indolent course of the disease 34, 36 .
Shared replacement mutations ("stereotyped" amino acid changes) at particular codon positions have been reported for a few subsets 34, 37 . 
PATIENTS AND METHODS

Patient group
A total of 1939 patients with CLL from collaborating institutions in Finland (n=33), France (n=756), Greece (n=452), Italy (n=178), Spain (n=59) and Sweden (n=461) were studied for IGHV repertoire and mutational status. All cases displayed the typical CLL immunophenotype as described earlier 25, 27 and met the diagnostic criteria of the National Cancer Institute Working Group (NCI-WG) 38 . Written informed consent was obtained according to the Helsinki declaration and the study was approved by the local Ethics Review Committee of each institution.
PCR amplification of CLL IGH rearrangements
In the vast majority of cases (1797/1939 cases; 93%), peripheral blood samples were analyzed; bone marrow (105 cases), lymph nodes (28 cases) and spleen specimens (9 cases) were also analyzed. Amplification and sequence analysis of IGH rearrangements were performed on either DNA or cDNA as previously described 25, 27, 34, 37 or using the BIOMED-2 protocol 39 . Sequence data was analyzed using the IMGT database and tools [40] [41] . All sequences were in-frame; any partial sequences that did not include the entire HCDR1 were excluded from the analysis.
Collection of non-CLL sequence data
Non-CLL IGH sequences were retrieved from the IMGT/LIGM-DB database in Table 1 ).
Sequence analysis and data mining
Both CLL and non-CLL sequence sets were submitted to the IMGT V-QUEST analysis software 41 to obtain gene and allele usage and mutation data. The following information was extracted:
1. IGHV gene usage, percentage of identity to germline, and HCDR3 length In order to account for the fact that a mutation is more likely to occur in a HFR than a HCDR simply due to its greater length, each mutation was 'weighted', or normalized, by the codon length of the region in which it occurred, e.g. an AA mutation in a HCDR1 of length 8 would be assigned a weight of 1/8, or 0.13. Subsequently, in order to compare mutation distributions between groups (IGHV genes, subsets etc), the sum of the normalized mutation counts per HFR/HCDR was expressed as a percentage of the total normalized mutation counts in the group. We describe these values as the "normalized distribution percentages" throughout Results.
Consequently, it was possible to compare mutation data (e.g. total mutations/R mutations/S mutations) per region (e.g. HCDR2, HFR3) or combinations of regions (HCDR1 and HCDR2), within/across different groupings of sequences (e.g. individual IGHV genes, homologous subsets and CLL vs. non-CLL sequences).
We extracted additional information on all AA changes codon-by-codon and examined whether the somatically introduced AA belonged to the same biochemical category as the mutating AA ("conservative" change) or not ("non-conservative" change).
3. Hotspot targeting.
Mutated sequences were also analyzed for targeting to the tetranucleotide (4-NTP) motifs RGYW/WRCY (R=A/G, Y=C/T, and W=A/T) 44 and DGYW/WRCH (D=A/G/T, H=T/C/A) 45 . To account for differences in germline composition, counts were normalized by evaluating the number of 4-NTP mutations per HCDR/HFR nucleotide length per 4-NTP position for each sequence. 
RESULTS
IGHV repertoire and mutation status
A total of 1967 in-frame IGHV-D-J sequences obtained from 1939 CLL patients were included in the analysis; 28 patients carried double in-frame rearrangements. Overall, this large and geographically diverse series confirmed previously published IGHV repertoire data obtained in smaller series [24] [25] [26] [27] 33 (Supplemental Table 2 ).
Following the 98% identity cut-off value, which is used to make the clinically relevant distinction between "mutated" and "unmutated" CLL cases [15] [16] [17] [18] [19] , 1064/1967 sequences (54%) from our series were defined as "mutated", whereas the remainder (903/1967 sequences, 46%) had "unmutated" IGHV genes. Of note, concordant mutational status was observed in both IGHV-D-J rearrangements in 15/28 cases with double in-frame rearrangements; in the remaining 13 cases, the two rearrangements had different mutational status.
We subdivided "unmutated" sequences into a "truly unmutated" subgroup, which included 677/1967 sequences (34.4%) with IGHV genes in germline configuration (100% identity), a "minimally mutated" subgroup, which included 133/1967 sequences (6.8%) with 99-99.9% identity to germline, and a "borderline mutated"
subgroup, which included 93/1967 sequences (4.7%) with 98-98.9% identity to germline. The IGHV repertoires of the "mutated", "minimally mutated", "borderline mutated" and "truly unmutated" subgroups differed (Supplemental Table 3 ), in keeping with previous reports [24] [25] [26] [27] 33 Table 4 ). In particular, the IGHV1-69 and IGHV1-2 genes predominated among, respectively, "truly unmutated" and "minimally mutated"
sequences. In contrast, other IGHV genes were mostly utilized in "mutated" (<98% identity) rearrangements (e.g., IGHV4-34, IGHV3-23, IGHV3-7). Finally, the IGHV3-21 and IGHV3-48 genes had the highest proportion of "borderline mutated" (98-98.9% identity) rearrangements. Significant differences were also observed with regard to mutation status among groups of sequences utilizing different alleles (39) of certain IGHV genes, in particular IGHV1-69, IGHV4-39 and IGHV3-30 (Supplemental Table 5 ).
"Truly unmutated" sequences had significantly longer HCDR3s (median 21 AA, range 4-32 AA) than all other sequences; a significant difference in HCDR3 length was also observed among "minimally mutated" (median 19 AA, range 9-29) and "borderline mutated" or "mutated" sequences (median 15 AA for both groups, range 9-30 AA) ( Figure 2 ) (p<0.001 for all comparisons). Table   6 ). At the level of individual genes of the IGHV1/3/4 subgroups, the highest normalized R/S mutation ratios in HCDRs were observed among sequences utilizing the IGHV4-59, IGHV3-15, IGHV4-4, IGHV3-21 and IGHV3-33 genes. In contrast, the lowest R/S mutation ratios in HCDRs were seen among IGHV4-39, IGHV4-34 and IGHV3-48 sequences (Supplemental Tables 7-8 ).
Targeting of somatic hypermutation
In particular, within the HCDR2, IGHV3-21 sequences had the highest R mutation targeting and the lowest S mutation targeting relative to all other genes. IGHV3-21
sequences also carried the lowest R mutation frequencies in all three FRs.
Conversely, IGHV4-34 sequences displayed the lowest R mutation frequency as well as the lowest R/S mutation ratio in HCDR2. As revealed by comparison to IGHV4-34 sequences from normal and autoreactive cells, the paucity of R mutations in HCDR2
is a "CLL-biased" feature ( Figure 3) .
A significantly higher clustering of R mutations to 4-NTP motifs in the HCDR2 were observed among IGHV3-vs. IGHV1-or IGHV4-expressing sequences (p<0.01). A significant bias for R mutation targeting to 4-NTPs was also evident in HFR3 of IGHV4-expressing sequences, as exemplified by markedly different targeting for AA changes of two consecutive, alternative serine codons. In particular, the AGC codon ("the hottest of SHM hotspots" [46] [47] ) at IMGT/HFR3-92 carried an AA change in 59% of mutated IGHV4 sequences, whereas the TCT codon at position IMGT/HFR3-93
carried an AA change in only 4% of sequences. Of note, the targeting of the AGC serine codon at IMGT/HFR3-92 was significantly higher in CLL vs. normal vs.
autoreactive IGHV4 sequences (59% vs. 39% vs. 23.6%; p<0.05).
Recurrent amino acid changes in subsets of CLL cases expressing stereotyped HCDR3 sequences
Analysis of sequences from the present series following previously described criteria 34 allowed us to identify 530/1967 sequences (26.9%) as belonging to 110 different subsets with stereotyped HCDR3 (Supplemental Table 9 ), of which 48 have been reported previously [27] [28] [29] [30] [31] [32] [33] [34] ; each subset included from two up to 56 cases. The frequency of sequences carrying a stereotyped HCDR3 was significantly higher among "truly unmutated" or "minimally mutated" (43.4% and 36.7%, respectively) vs.
"borderline mutated" (24.7%) vs. "mutated" (15.5%) sequences (p<0.001 for all comparisons).
Shared ("stereotyped") AA changes (i.e., the same AA replacement at the same position) across the whole IGHV gene sequence were identified for subsets of CLL sequences with stereotyped HCDR3s. As revealed by comparison of the CLL vs.
non-CLL datasets, certain AA changes could be considered as "CLL-biased".
Furthermore, for certain IGHV genes, many stereotyped AA changes occurred significantly more frequently in cases with stereotyped rather than heterogeneous HCDR3 sequences and, therefore could be considered as "subset-biased" (Table 1) .
A comprehensive list of such stereotyped AA changes is provided in Supplemental   Table 10 . The most striking "CLL-biased" hypermutations were observed in the following subsets of sequences with stereotyped HCDR3s:
(1) Nineteen sequences from the present series utilizing allele *02 of the IGHV1-2 gene belonged to two subsets with stereotyped HCDR3s [32] [33] [34] . The first subset (#1) included 53 minimally mutated / truly unmutated sequences which utilized IGHV genes of the same clan (IGHV1-2/IGHV1-3/IGHV1-18, IGHV5-a, IGHV7-4-1). Among 15 IGHV1-2*02-expressing sequences of this subset, 9 had 100% identity to germline whereas 6 were found to carry a single replacement mutation, leading to a W-to-R change at IMGT/HFR2-55 ( Figure 4A ). The second subset (#28) included 5 IGHV1-2 sequences with stereotyped HCDR3s of which one utilized allele *01 and had 100% identity to germline, whereas four utilized allele *02 (as previously described [33] [34] ) and carried the same single replacement mutation as described above for the subset #1. Comparison of "subset" IGHV1-2*02 sequences to CLL IGHV1-2*02 sequences with heterogeneous HCDR3 or non-CLL IGHV1-2*02 sequences demonstrated that the W-to-R change was "subset-biased". In two cases of this (4) were "subset-biased" (Table 1) . Remarkably, within CLL, subset #2 cases had a higher targeting of the HCDR2 than non-subset-#2 IGHV3-21 cases (Supplemental Table 11 ). sequences demonstrated that three of the four stereotyped AA changes were "subset-biased" (Table 1 ). Similar to subset #2, subset #4 and subset#16 sequences also showed distinctive SHM distribution "profiles" in the HCDRs/HFRs compared to IGHV4-34 sequences with heterogeneous HCDR3s. In particular, subset #4 IGHV4-34 sequences displayed a notably higher targeting of HFR2 and HCDR1 than IGHV4-34 sequences with heterogeneous HCDR3s; subset #16 cases also demonstrated a notably higher targeting of the HCDR1 than IGHV4-34 sequences with heterogeneous HCDR3s (Supplemental Table 11 ).
(3) Among a subset of four IGHV4-4-expressing sequences with stereotyped HCDR3s (subset #14) 34 , six different recurrent mutations were observed in 75-100%
cases (Figure 4-E). Comparison to CLL IGHV4-4 sequences with heterogeneous
HCDR3s or non-CLL IGHV4-4 sequences demonstrated that all the above AA changes were "subset-biased" (Table 1) .
Mutation targeting of superantigenic-binding motifs
(1) A total of 706 IGHV3-expressing cases with <100% identity to germline were examined for SHM targeting to the IGHV3-specific motif responsible for Staphylococcal protein A (SpA) binding, which is mediated by a conformational surface generated by AAs at 13 positions in the V region of IGHV3 subgroup genes 5 .
Non-conservative residue variations at 2 or more positions of this motif result in loss two or more non-conservative AA changes of the motif and neither of these belonged to subset #2. In contrast, though also relatively infrequent, up to three quarters of AA changes identified in rearrangements of other IGHV3 genes (even those with a similar mutation load as the IGHV3-21 rearrangements) could be non-conservative.
(2) A total of 126 IGHV4-34 sequences with <100% identity to germline were examined for SHM targeting to the IGHV4-34-specific motif responsible for carbohydrate I binding, which is mediated by a hydrophobic patch in HFR1 involving residue W7 on β -strand A and the AVY motif (residues 24-26) on β -strand B 48 .
Notably, few IGHV4-34 sequences were altered at the four positions of the anti-I/i motif. Overall, there were only 0.9-4.9% non-conservative AA changes at these codon positions and only one sequence had an AA change at more than one of the motif positions.
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DISCUSSION
In the present study, 1967 IGHV-D-J sequences from 1939 patients with CLL were analyzed for SHM patterns and compared to public non-CLL sequences from the IMGT database. Our series consisted of mutated and unmutated sequences at a frequency reported as typical for CLL [18] [19] 24, [26] [27] . The gene repertoire of "truly unmutated" (100% identity to germline) CLL sequences of the present series (n=677) was extremely skewed and also characterized by significantly longer HCDR3s. Furthermore, 43.4% of "truly unmutated" sequences were found to belong to a subset with stereotyped HCDR3s. These observations suggest that the unmutated state in CLL could reflect selective pressures for maintaining germline configuration 28, 49 . Unmutated BCRs of CLL B cells have recently been shown to be associated with autoreactivity and polyreactivity against molecules such as DNA, insulin and LPS, whereas BCRs in mutated CLL did not exhibit these polyreactive properties 50 .
Furthermore, as previously shown, the antigen binding site excluding the HCDR3 is exceptionally cross-reactive, at least until acted on by SHM [51] [52] . Based on the findings of the aforementioned studies and the results of the present study, it could perhaps be reasonable to speculate that unmutated BCRs with multiple specificities may provide CLL progenitors with a selective advantage because they widen the spectrum of potential antigenic stimuli [53] [54] .
Previous studies in both normal and autoreactive B cells have shown that even a few mutations may be functionally relevant [55] [56] [57] . Along these lines, in the present study, we also explored potential biological implications of low mutational "load" in CLL.
Therefore, SHM analysis was undertaken for the cohort of all 1290 sequences of the present series with <100% identity to germline. At the cohort level, SHM patterns were typical of a canonical SHM process 6, [46] [47] [58] [59] . However, important differences Table 12 ). These findings illustrate that even very slight alterations in IG sequence appear to be selected for, perhaps because they may confer a clonal advantage. sequences, all expressing stereotyped BCRs. This finding confirms and extends a recent report from our group, which first suggested that this deletion is "CLL-biased" 37 . Therefore, while IGHV3-21 sequences are generally less targeted by SHM than other IGHV3 genes, the observed mutations appear to be very precisely and effectively targeted, indicating selection by specific antigen(s). Along these lines, it is also perhaps relevant that IGHV3-21 sequences from our series, in particular those carrying stereotyped HCDR3s, showed a strong tendency to retain germline configuration in the binding motif for Staphylococcal protein A, the prototype for a class of naturally arising proteins that have the properties of model B-cell superantigens 5 . At present, the biological and clinical implications of this observation , if immature IGHV4-34-expressing B cells participate in the uptake of apoptotic cell remnants in the bone marrow, at the same time, they must be undergoing modifications to ablate self-reactivity 68 . These modifications may be introduced by somatic diversification mechanisms, such as SHM and receptor editing 66, [69] [70] . In the present study, 79% of IGHV4-34 CLL sequences were mutated, in keeping with previous reports in smaller series 24, [26] [27] 34 . In line with the reasoning presented above, this trend might reflect the fact that IGHV4-34 sequences must undergo SHM in order to negate their autoreactivity and be sufficiently "safe" to be HCDR3 sequence motifs enriched in basic amino acids have been shown to correlate strongly with reactivity of IGHV4-34 antibodies against both B cells and DNA [73] [74] [75] . All subset #4 IGHV4-34 CLL sequences from our series have high HCDR3
isoelectric point values and all carry a couplet of basic residues (arginine-arginine or arginine-lysine) at the IGHD-IGHJ junction. High isoelectric point, overall positive charge, and increased numbers of arginine residues are frequent features of many pathogenic anti-DNA antibodies 57, [76] [77] [78] . Although it is not possible to accurately predict IG specificity by sequence analysis alone, these findings suggest that subset #4
BCRs may have anti-DNA specificity.
In transgenic mouse model systems, introduction of acidic residues (particularly aspartic acid) by SHM is a means to edit anti-DNA reactivities 56, 69, 79 . A remarkable HFR1 motifs. Therefore, in principle, CLL progenitors could be activated or "kickstarted" on infection or reactivation by certain microbial pathogens (CMV or EBV might be such pathogens [80] [81] [82] [83] [84] ) and thus receive signals promoting survival, expansion, malignant transformation, and potentially clonal evolution.
In conclusion, groups of patients with CLL utilizing certain IGHV genes -in particular subsets grouped according to HCDR3 composition -evidently carry shared, "stereotyped" mutations across the entire IGHV gene sequence. Furthermore, the mutation pattern within these subgroups was not only gene-and subset-biased, but also, in most cases, "CLL-biased". The finding of such "stereotyped" mutations in mutated CLL sequences carrying stereotyped HCDR3s indicates that the leukemic progenitor cells may have responded in a similar fashion to the selecting antigen(s).
Remarkably, as shown in the present study, selection for individual mutations is evident even in subsets with minimally mutated sequences, indicating a functional purpose for these modifications. Finally, the presence of stereotyped mutations is strong evidence that not only the HCDR3 but also other regions of the IG molecule could actively participate in antigen recognition and thus be involved in the development and evolution of the CLL clone. [85] [86] to summarize a total of 106 sequences belonging to these selected subsets (Supplemental Table 10 Table 1 and Supplemental Table 10 . For clarity, only codons 27 to 104, corresponding to HCDR1-HFR3 of the V region, are
shown. In (B), the letter X denotes the Serine deletion at IMGT/HCDR2 codon 59.
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TABLES
b All IGHV4-34 cases except for those belonging to subsets#4 and #16.
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